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Abstract
Background: Core Outcome Sets (COS) are defined as the minimum sets of outcomes that should be measured
and reported in all randomised controlled trials to facilitate combination and comparability of research. The aim of
this review is to produce an item bank of previously reported outcome measures from published studies in
amblyopia, strabismus and ocular motility disorders to initiate the development of COS.
Methods: A review was conducted to identify articles reporting outcome measures for amblyopia, strabismus and
ocular motility disorders. Using systematic methods according to the COMET handbook we searched key electronic
bibliographic databases from 1st January 2011 to 27th September 2016 using MESH terms and alternatives
indicating the different subtypes of amblyopia, strabismus and ocular motility disorders in relation to treatment
outcomes and all synonyms. We included Cochrane reviews, other systematic reviews, controlled trials, non-
systematic reviews and retrospective studies. Data was extracted to tabulate demographics of included studies,
primary and secondary outcomes, methods of measurement and their time points.
Results: A total of 142 studies were included; 42 in amblyopia, 33 in strabismus, and 68 in ocular motility disorders
(one study overlap between amblyopia and strabismus). We identified ten main outcome measure domains for
amblyopia, 14 for strabismus, and ten common “visual or motility” outcome measure domains for ocular motility
disorders. Within the domains, we found variable nomenclature being used and diversity in methods and timings
of measurements.
Conclusion: This review highlights discrepancies in outcome measure reporting within published literature for
amblyopia, strabismus and ocular motility and it generated an item bank of the most commonly used and reported
outcome measures for each of the three conditions from recent literature to start the process of COS development.
Consensus among all stakeholders including patients and professionals is recommended to establish a useful COS.
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Background
Amblyopia, strabismus and ocular motility disorders
occur in about 10% of the general population (amblyopia
2–5%, strabismus 4%) [1]. They often present as child-
hood conditions and can constitute long-term problems
for children and young adults. Strabismus and ocular
motility disorders can also develop as acquired condi-
tions due to neurological, endocrine and traumatic
causes. There are several approaches to the management
of these conditions including occlusion, penalisation,
spectacles, prisms, drugs, surgery, botulinum toxin, exer-
cises, watchful waiting, or a combination of two or more
of the above [2]. The effects from these treatments such
as improvements in symptoms or side effects are
assessed by outcome measures and are usually used to
formally evaluate management options in clinical stud-
ies. However varied outcome measures and several end-
points are often used [3–5]. This lack of standardisation
makes it difficult to compare the conclusions of these
studies and, as a result, renders it challenging to discuss
realistically the likely outcomes of treatment with pa-
tients in the clinic [6].
One strategy suggested to overcome the issues result-
ing from variable outcome measures is the development
of Core Outcome Sets (COS). This is defined as the
minimum set of outcomes that should be measured and
reported in all randomised controlled trials [7]. The
COS will make it easier for the results of trials to be
compared, contrasted and combined, lead to research
that is more likely to have measured relevant outcomes
due to involvement of relevant stakeholders, and en-
hance the value of evidence synthesis by ensuring that
all trials contribute usable information [7]. Therefore, it
is postulated that the use of COS would increase the po-
tential in carrying out future meta-analysis for target
conditions.
The numerous and diverse outcome measures that
may be used for amblyopia, strabismus and ocular motil-
ity disorders include, amongst others, visual acuity, angle
of deviation, range of ocular movements, fixation stabil-
ity and binocular vision measurements. There are a
number of Cochrane systematic reviews that consider a
range of treatment trials for amblyopia, strabismus and
ocular motility disorders. Their recommendations call
for clarification of dose/response effect and further in-
vestigation of treatment regimens [2–4]. An attempt to
utilise a COS is evident for the National Strabismus Data
Set project [8]. A recent review recommended four out-
comes for reporting results of surgery for intermittent
exotropia [5] but was limited by the extent of literature
review and lack of external consensus. A short narrative
review of outcome measurements for size of deviation
showed considerable variability across the tests available
and the recommendations for their use [9].
Development of a COS involves a number of stages
that commence with a systematic review of the literature
to identify existing knowledge about outcome measures
[7]. This is then followed by qualitative studies, Delphi
surveys to consult widely on outcome measures and fi-
nally, consensus meetings to discuss and agree on the
COS [7]. This paper reports the first stage – the litera-
ture review to identify the reported range of outcome
measures in the published literature for amblyopia, stra-
bismus and ocular motility disorders.
Objectives
The primary aim of this review is to generate an item
bank of relevant outcome measures previously reported
by researchers and clinicians in studies of treatment of
conditions under evaluation. The review aims also to de-
termine the variation in measuring methods used and
timings of assessments.
The secondary objectives of this review are to investi-
gate sources of variability of outcome measure defini-
tions including different age groups, study designs, types
of amblyopia (e.g. refractive, strabismic, stimulus
deprivation), types of strabismus (e.g. exotropia, esotro-
pia), and types of ocular motility disorder (e.g. accom-
modation and convergence disorders, mechanical
restrictions, myogenic, neurogenic, nystagmus, patterns
deviation and gaze palsy).
Methods
A protocol for the development of this COS project was
written by a steering committee – a team of stakeholders
including COS developers, ophthalmologists, orthoptists
and journal editors. The review protocol was registered
in the COMET initiative website (http://www.comet-ini-
tiative.org/studies/details/900?result=true) and published
as open access (http://pcwww.liv.ac.uk/~rowef/index_-
files/Page356.htm). The review, using systematic rigor-
ous methods, was conducted in accordance with the
guidelines from the COMET handbook [7]. A PRISMA
checklist [10] has been completed for the systematic re-
view and can be found in Additional file 1 : Table S1.
Eligibility criteria
Age
Subjects of all ages with target conditions were included.
Target conditions:
1. Amblyopia (unilateral, bilateral) of any type or
severity (refractive, meridional, ametropic,
strabismic or stimulus deprivation).
2. Strabismus (latent, manifest, constant, intermittent,
micro) of any type and severity (eso, exo, hyper,
hypo, cyclo deviation)
Jabri et al. BMC Ophthalmology           (2019) 19:47 Page 2 of 22
3. Ocular motility disorders (OMDs) of any type and
severity (nystagmus, horizontal/vertical gaze palsy,
cranial nerve palsy, convergence/divergence
disorder, patterns of horizontal incomitance,
mechanical restrictions, myogenic disorders like
thyroid eye disease and myasthenia with ocular
involvement).
We included all three target conditions in recognition
of the considerable overlap between them, for example
amblyopia and strabismus often coexist with presenta-
tion in childhood with frequent persistence to adult life;
whilst strabismus and ocular motility disorders often co-
exist with onset at any age through childhood and adult
life.
Interventions
We included any intervention that aimed to improve the
conditions of amblyopia, strabismus and ocular motility
disorders or alleviate their associated visual symptoms.
Interventions may include prisms, occlusion, optical
penalisation, glasses, exercises, behavioural vision train-
ing, extraocular muscle surgery, extraocular muscle in-
jection of botulinum toxin, pharmacology therapy, and
watchful waiting/observation.
Comparisons
We included any comparison between the effectiveness
of a treatment modality with another or with no treat-
ment for each condition.
Outcome measures
We included any reported outcome measure that was
recorded using any possible instrument or method at
any point of time from the intervention.
Types of studies
The following types of studies were considered to be in-
cluded in this review:
• Cochrane systematic reviews
• Systematic reviews (with or without meta-analysis)
inclusive of diagnostic test accuracy reviews
• Randomised controlled trials (RCT)
• Controlled clinical trials (CCT)
• Cohort studies
• Case series with > 10 subjects
We excluded all case reports and letters/editorials.
Search methods for identification of studies
We used systematic strategies to search key electronic
databases. We searched Cochrane registers and elec-
tronic bibliographic databases including CENTRAL, ovid
MEDLINE, SCOPUS, CINAHL, AMED and PsycINFO
with search dates of 1st January 2011 through to 27th of
September 2016. This period was selected given the con-
siderable increase in studies, trials and reviews in recent
years and to extract treatment outcome measures that
are relevant to recent research and clinical practice. As
per COMET handbook guidance [7] we recognised that
overly large reviews would be resource intensive and
might not yield important additional outcomes.
We did not search for unpublished studies or in clin-
ical trials registries and we did not hand-search any add-
itional resources. We performed citation tracking using
Web of Science Cited Reference Search for all included
studies and searched the reference lists of included trials
and review articles. Studies identified from the combined
search were exported to an EndNoteX7 library. Search
terms included a comprehensive range of MeSH terms
and alternatives.
SJ and senior author FR developed the table of search
terms jointly to include all target conditions and all syn-
onyms of outcome measures, outcomes or assessments.
Appropriate Boolean operators were obtained using Uni-
versity of Liverpool library online resources. Whenever
available, the filters of “limit to humans” and “exclude
case reports” were applied to the search in the databases.
An example for search terms for one database is out-
lined in Additional file 2: Table S2. There was no lan-
guage restriction while carrying out the search. The
search strategy was discussed with and approved by the
study steering committee.
Selection of studies
During the first stage of selection, SJ screened the titles
and abstracts identified from the search that had been
exported to an EndNoteX7 database. Senior researchers
(FR and JJK) were consulted when there was a doubt
about any abstract. Full text papers were accessed for all
papers whose title and/or abstract met the eligibility cri-
teria. These full text papers of potentially relevant stud-
ies were considered in the second stage of selection in
which the selection criteria were again applied to the full
paper content. We resolved disagreements by discussion.
The study protocol was registered in the COMET ini-
tiative website. We planned to include systematic re-
views, controlled trials, non-systematic reviews,
prospective and retrospective cohort studies as well as
case series with > 10 subjects at the time of writing the
protocol for this systematic review. However this was
not done in the actual review (protocol deviation) due to
the excessive number of studies that met the inclusion
criteria from the higher quality papers of systematic re-
views and RCTs/CCTs for most conditions (Fig. 1).
Only a sample of non-systematic reviews and cohort
studies was used (as the next best evidence quality to
RCTs/SRs) to supplement this review when the number
of studies from RCT/SRs for a particular sub-condition
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was sparse. We performed this also to check for any po-
tentially important missed outcome measures from
RCTs/SRs, e.g. long-term outcome measures or adverse
events. The sample was variable depending on the avail-
ability of articles within the search results pertaining to a
certain condition. The sample was increased until out-
come measure saturation was achieved, defined as when
no additional new measures could be identified and they
were repetitive across studies. One non-systematic re-
view and four retrospective studies for the ocular motil-
ity disorder sub-condition “pattern deviation” were
included as we could not identify any relevant RCTs/SRs
from the search results.
Data extraction
SJ extracted the data using a pre-determined data extrac-
tion form. Senior reviewer FR reviewed 20% of studies to
confirm fulfilling data extraction. There were no dis-
agreements or inconsistencies.
The following data was extracted from each study:
Demographics
1. Study type.
2. Author details.
3. Year and journal of publication.
4. Country where study was conducted.
5. Condition(s) under investigation (amblyopia/
strabismus/ocular motility disorder).
6. Age of participants in the study population.
Outcome measures
1. The designated outcome measure (primary and
secondary).
2. Outcome measurements (methods or instruments
of measurements).
3. The time points at which they were measured.
Data analysis and presentation
All data was extracted verbatim from the source manu-
scripts to facilitate external critical review of the COS
right back to its inception. Different nomenclature or as-
pects used to indicate the same outcome measure were
grouped within main outcome headings (domains) when
applicable to facilitate easy classification of outcome
measures. For example for amblyopia the following as-
pects were recorded under the outcome measure head-
ing of visual acuity (VA): best corrected visual acuity
(BCVA), near visual acuity and binocular visual acuity.
They were all recorded as reported in individual studies
and then grouped together under one main outcome
measure (VA). The method of measurement for BCVA
was reported; e.g. using “Electronic Early Treatment
Diabetic Retinopathy Study (ETDRS) VA protocol” or
“Snellen chart” etc. and in addition we recorded the time
when the measurement was made.
A similar classification and tabulation of information
regarding the different outcome measures for the differ-
ent conditions and sub-conditions was used. For the
purpose of this study we did not perform a quality as-
sessment for outcome data from the included studies as
we sought only to create an item bank of all utilised out-
come measures and outcome measurements. Hence a
critique of the methodological quality of the studies was
not necessary [7].
Fig. 1 Flowchart of selection process
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We generated an item bank of relevant outcome mea-
sures for amblyopia, strabismus and ocular motility dis-
orders presented in percentages of frequency in included
studies. In addition we produced an inventory of
methods of measurements and their timings. Ocular
motility disorders outcome measures were further strati-
fied by sub-condition.
Results
Study selection
Electronic search of the six databases returned 22,217
hits, which were exported to the reference manager
“EndNote X7”. Titles were screened and the number re-
duced after removing duplicates and non-relevant papers
to 2982 reports (Fig. 2). Another 1260 papers were ex-
cluded after screening the abstracts.
We were left with 1722 potentially relevant reports to
our review question and meeting our eligibility criteria
in review protocol (systematic reviews, controlled trials,
cohort studies, and case series with > 10 patients for tar-
get conditions and populations). Due to the large num-
ber of the potently eligible papers, we considered a
modification to our eligibility criteria stated previously
in the study protocol. We consulted the COMET hand-
book in which it is suggested, as an option, to perform
the systematic review in stages to check if outcome sat-
uration is reached [7] We took a decision, as a first stage
analysis (protocol deviation, Fig. 1), to include only sys-
tematic reviews and controlled trials initially. This pre-
sented us with a total of 165 studies. Out of those, 53
studies were excluded after reading full articles due to ir-
relevance or lack of “visual or ocular motility” outcomes
leaving us with 112 eligible systematic reviews and trials.
Then, when no systematic reviews or trials were found
to cover a particular sub condition, cohort studies were
considered as the next stage of the analysis. Moreover,
we included additional non-systematic reviews distrib-
uted across the different conditions and sub conditions
Fig. 2 Study search
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of motility disorders to ensure a comprehensive litera-
ture review and data saturation. The included number of
both cohort studies and non-systematic reviews was 30
in total (4 cohort and 26 non-systematic reviews).
The total number of studies included in analysis in this
review eventually was 142 unique studies. The studies
came from a wide range of countries with predominance
from the United States, the United Kingdom, China and
various European countries (Fig. 3).
The following sections will present our findings indi-
vidually for each of the three conditions: Amblyopia,
Strabismus and OMDs outlining types of included stud-
ies, types of the conditions, age groups and treatments
and listing outcome measures, measurements and
commenting on timings. Further subgroup analysis is
carried out for OMDs sub-conditions.
Amblyopia
Types of included studies
In this review we looked at a total of 42 studies in am-
blyopia including six Cochrane reviews, eight systematic
reviews and meta-analysis, 24 controlled trials and four
non-systematic reviews.
Types of amblyopia and included age groups
The types of amblyopia targeted in included studies
ranged from childhood amblyopia [1, 11–42] to residual
amblyopia in older children [43, 44], adolescents or
Fig. 3 Distribution of included studies by countries where they were conducted
Jabri et al. BMC Ophthalmology           (2019) 19:47 Page 6 of 22
adults [40, 41, 45, 46], unilateral [3, 12] and bilateral [3],
refractive [3], anisometropic [19, 23], strabismic [24, 47],
and stimulus deprivation amblyopia [48].
Types of treatment
Interventions varied from the “gold standard” refractive
correction and occlusion or atropine penalization [24,
27, 30, 31] to the more modern controversial treatments
such as low-level laser [46], photic stimulation [43], and
medical and behavioural treatment [45] which were
more likely to be used beyond the visual maturation age
when conventional treatments often fail.
Occlusion dosages and approaches were investigated
in a number of included studies such as part-time versus
full time occlusion [38], personalized versus standardized
[33], and occlusion versus Bangerter filters [23]. Atro-
pine penalization versus patching, and atropine com-
bined with plano lenses were investigated in three of the
included studies [20, 31, 34].
Binocular training with interactive computerized
games or video clips versus monocular occlusion treat-
ment were under investigation in seven studies [12, 22,
25, 28, 35, 36, 40]. Levodopa was the main treatment
used in two studies [16, 44] and Citocolin combined
with patching was used to treat residual amblyopia in
older children in one of the included studies [29]. Acu-
puncture and Chinese medicine were the main thera-
peutic intervention for amblyopia in six of the included
[11, 18, 19, 21, 32, 49].
Outcome measure domains
We identified ten domains of outcome measures in these
studies (Table 1): “visual acuity” (86%), “stereopsis or
sensory outcomes” (40%), “adverse events” (33%), “heal-
th-related quality of life” (HRQoL) (21%), “compliance”
(19%), “refractive outcomes” (12%), “ocular alignment”
(10%), “economic data” (7%), “visual evoked potential”
(VEP) (5%), and “detection by photoscreeners” (2%).
Outcome measure subdomains and measurements
Visual acuity The majority of studies (86%) measured
visual acuity (VA) as the primary outcome measure.
Variable descriptions used included improvement in VA
[11, 18, 25, 28, 32, 35, 39, 45, 47], mean VA [3, 12, 13,
23, 40, 44, 48], median change in VA [23, 24], and “an
increase of two or more lines of visual acuity or a final
visual acuity of 20/25 or better” [20]. We identified a mi-
nority of subdomains of the outcome VA being reported
by single studies such as near VA to compare it to dis-
tance visual acuity prior to amblyopia treatment [17]
and “binocular VA” [39].
The LogMAR unit was universally used by all studies
to report VA (n = 38) however different charts and
distances were used depending on varying factors such
as participant’s age or setting. Relative to studies that
specified which charts were used, the most commonly
reported tests were “Isolated Crowded Amblyopia Treat-
ment Study HOTV for subjects aged 3 to < 7 years” [14,
17, 27, 34, 39, 44, 45] and “Electronic Early Treatment
Diabetic Retinopathy Study VA protocol for subjects
aged 7 or older” [14, 27, 34, 44, 45]. “Snellen chart” was
reported as an alternative by a lesser number of studies
[14, 16, 39, 45] and “Crowded Acuity Test” was used in
two studies [30, 43].
Stereopsis/sensory outcomes These were reported in
17/42 (40%) of the studies. In one study “stereo-sensitiv-
ity” was reported rather than stereopsis, in order to be
able to represent nil stereoacuity by zero, which there-
fore can facilitate quantitative analysis as suggested by
Tsirlin et al. [45].
Seven out of 17 of the studies did not report a particu-
lar outcome measurement, however the unit was given
as “seconds of arc” in six studies [11, 12, 20, 23, 28, 42].
To measure near stereoacuity, “Randot Preschool test”
was reported in four studies [27, 31, 34, 45], “Frisby test”
in two [26, 45], and “Lang stereo test II” in two studies
[23, 24]. “Bagolini glasses at distance & near” was used
in addition, to determine lower levels of binocularity in
the same previous two studies by Agervi et al. [23, 24].
Adverse events The reported variants of this outcome
measure included “diplopia” [12, 35, 47, 48], “occlusion
amblyopia” [12, 47], “visual disorientation” [47], “skin ir-
ritation” [15], and “allergy to patches” [47, 48]. Adverse
events were assessed using “a survey containing 17 items
with a Likert scale completed by child and parent” in the
RCT of Levodopa in older children by the Pediatric Eye
Disease Investigator Group (PEDIG) [44]. The remaining
studies did not give a particular method to gather this
outcome measure.
HRQoL This is increasingly being reported as an out-
come measure in the treatment of amblyopia. The stud-
ies reported more than ten different instruments. The
most commonly reported questionnaire in these was
“The Amblyopia Treatment Index (ATI)” [37, 41, 50,
51].
Compliance This was assessed using “objective occlu-
sion dose monitoring” in three studies [12, 30, 37], by
discussions with the parent [34], or review of a calendar
log maintained by the participant and parent [44].
Ocular alignment Interestingly ocular alignment was
not reported as an outcome measure in the majority of
the included studies (88%), even for strabismic
Jabri et al. BMC Ophthalmology           (2019) 19:47 Page 7 of 22
amblyopia. However, it was highlighted in the PEDIG
trials where it was measured using a “simultaneous
prism and cover test” [27, 31, 34, 44] and in one
Cochrane review where it was measured using “cover
test” [42].
Refractive outcomes “Median spherical equivalent” [14,
23, 24] and “spherical and cylindrical refraction” [13]
have been reported in included studies.
Visual evoked potential (VEP) VEP was reported as a
secondary outcome in addition to visual acuity in the
study conducted by Ivandic et al. after the use of low laser
for adolescents and adults with amblyopia [46]. “Multi-
focal visual evoked potentials (M-VEP) amplitude and la-
tency” was measured in a number of the subjects in the
trial. Another example of using “VEP latency” as an out-
come measure was reported by Yang et al. in a
meta-analysis looking at studies that used Levodopa in the
treatment of amblyopia in children < 18 years of age [16].
Timing of measurements
We found variable timings that ranged from six weeks
(post binocular training) [35, 40] to three years (post
Table 1 Amblyopia outcome measures and measurements
Outcome measure
domain
Studies reported the outcome
measure (n/42)
Variable subdomains of outcome
measure
Variable outcome measurements References
Visual acuity 36 (86%) BCVA (median/ mean change,IOD,≥2 line
improvement) 38
Uncorrected Distance Visual Acuity UDVA
1
Near Visual Acuity 1
Binocular VA 1
Age appropriate test 23
HOTV 7
ETDRS 5
Snellen eye chart 4
The Crowded Acuity Test
(Glasgow Acuity Test) 2
Tumbling E charts 2
Bailey-Lovie 1
Allen Figs. 1
[3, 11–20, 22–34, 36–40, 43–48]
Stereopsis 17 (40%) Near Stereopsis/
binocularity/sensory outcomes 16
Stereo sensitivity 1
Randot Preschool Stereoacuity
Test 4
Lang stereo test II 2
Bagolini glasses response (at near
& distance) 2
The Frisby test 2
[11, 12, 15, 20, 23–28, 31, 34, 36,
39, 42, 45, 48]
Adverse events 14 (33%) [3, 11–13, 15, 16, 25, 27, 34, 35,
44, 47–49]
Health-related
quality of life
9 (21%) HRQoL 9
Emotional impact 1
Social stigma scores 1
Amblyopia Treatment Index 4
Amblyopia
and Strabismus Q 2
Psychological Impact Q 2
Patching Success Q 1
CVFQ 1
SPPC 1
VF-14 1
Protection Motivation Theory Q 1
Interviews 1
Mean Rutter behaviour scores 1
[3, 11, 12, 15, 37, 41, 47, 48, 50]
Compliance 8 (19%) Objective occlusion dose
monitoring 3
Parental treatment diaries 2
[12, 15, 25, 27, 30, 34, 37, 44]
Refractive outcomes 5 (12%) Median spherical equivalent 3
Refractive outcome 2
Spherical and cylindrical refraction 1
Manifest and cycloplegic
refractions 1
[13, 14, 23, 24, 31]
Ocular alignment 5 (12%) Simultaneous prism and
Cover test SPCT 4
Cover test 1
[27, 31, 34, 42, 44]
Economic data 3 (7%) Cost data 3
Cost- effectiveness 1
[3, 47, 48]
Visual evoked
potentials
2 (5%) M-VEP amplitude & latency 1
VEP latency 1
[16, 46]
Detection by
Photoscreeners
1 (2%) MTI photoscreener 1
PowerRefractor 1
PowerRefractor II 1
Plusoptix photoscreener series 1
iScreen 1
Spot 1
[1]
BCVA, Best Corrected Visual Acuity, IOD inter-ocular difference, ETDRS Electronic Early Treatment Diabetic Retinopathy Study, UDVA Uncorrected Distance Visual
Acuity, HR-QoL Health-related quality of life, Q questionnaire, CVFQ Children’s Visual Function Questionnaire, SPPC Self-Perception Profile for Children, VF-14 Visual
Function Index, VEP Visual Evoked Potential, M-VEP multifocal VEP
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strabismus surgery in amblyopia [42], and post auricular
point sticking therapy [18]. However 10 weeks [25, 27,
34], 6 months [11, 32, 40] and 12months [3, 12, 29, 47,
48] were the commonest timings given. Long-term out-
comes were measured at 15 years of age in the RCT of
“Atropine vs patching for treatment of moderate ambly-
opia” by the PEDIG [31] and at seven years of age in the
review of “Occlusion for stimulus deprivation ambly-
opia” [48].
Strabismus
Types of included studies
We included 33 strabismus studies distributed as nine
Cochrane reviews, four systematic reviews,13 controlled
trials, and seven non-systematic reviews.
Types of strabismus and included age groups
This review included outcome measures extracted from
studies investigating a wide range of strabismus types in
different age groups.
While strabismus in general was under evaluation in
around one third of the included studies (33%), intermit-
tent exotropia by itself was the focus in more than one
third (36%). This might be a reflection of the fact that
intermittent exotropia is a common form of childhood
exotropia [52]. Moreover, it is well established that it is
one of the commonest worldwide constituting around
25% of all strabismus types [5].
On the other hand, esotropia was the target condition
in only five studies (15%) with “Infantile esotropia” being
the type in four of them [53–56] and “High AC/A ratio
esotropia in teenagers” in one [57]. Three vertical stra-
bismus studies were also among studies included in our
review; two on dissociated vertical deviation (DVD)
management [58, 59] and another on inferior oblique
overaction [60].
The majority of subjects targeted in included strabis-
mus studies were from the paediatric age group. In this
review more than half of strabismus studies had children
less than 18 years of age as participants compared to
only 12% for adults [61–64]. The remaining studies were
either generalised for adults and children [2, 4, 5, 58, 60,
65–68] or did not state a specific age group [52, 59, 69].
Types of treatment
Over half of the studies (52%) discussed outcome mea-
sures following surgical interventions for strabismus,
most commonly muscle surgery (45%) [5, 42, 55, 56, 60,
61, 64–72] and less for botulinum toxin injection [2, 54].
Muscle surgery and botulinum toxin injection were both
combined in one study [63]. In contrast, non-surgical or
conservative treatments were evaluated in five of in-
cluded studies (15%) [52, 57, 73–75]. Another 15% of
studies involved both surgical and non-surgical
interventions and reported treatment outcome measures
following either method [4, 53, 58, 59, 76].
Outcome measure domains
We identified 14 domains of outcome measures for stra-
bismus (Table 2). The four most commonly reported
ones were “motor alignment” (79%), “binocularity”
(64%), “adverse events” (61%), and “health-related quality
of life” (48%). The less commonly reported outcome
measures included “visual acuity” (24%), “control of de-
viation” (24%), “fusional vergence” (15%), “ocular move-
ments” (9%) and “AC/A ratio” (3%).
Outcome measure subdomains and measurements
Motor alignment/angle of deviation This was reported
as “motor alignment” or “angle of deviation” in 26/33
studies. This was further described to be measured “at
near and distance” in seven studies out of these [4, 5, 63,
66, 70, 71, 77].
In 12 studies alignment was measured using “prism al-
ternate cover test PACT” [4, 5, 54, 58, 59, 63, 67, 70, 71,
74, 77, 78] and /or with “simultaneous prism cover test
SPCT” in eight studies [4, 53, 63, 66, 74, 75, 77, 79].
“Cover test” was reported in five studies [2, 42, 73, 74,
79], “Synoptophore” in four [2, 4, 42, 53] and “Hirsch-
berg test” in three [54, 73, 79]. Krimsky test was re-
ported as an alternative test in subjects with poor
cooperation in one study [54], when cover tests are not
applicable [63] or in cases with poor vision (worse than
20/200) in one RCT [60].
It is noteworthy that there is still no total agreement
on the definition of a successful ocular alignment [5],
varying from 5 to 8 to 10 PD from orthophoria. How-
ever there was a considerable agreement on defining
success in included studies as orthophoria within 10 PD
[2, 42, 53, 61, 65, 74, 80].
Stereopsis/sensory outcomes Sensory outcomes were
either reported as any level of “binocularity/stereopsis”
[2, 52, 55, 57–59, 67], or as “stereoacuity” (near or pre-
sumably near) [5, 56, 60, 71, 73, 76, 77, 79], or both; with
“binocularity” and “stereoacuity” stated as two distinct
outcome measures [42]. Additionally, “steroacuity at
near and distance” was measured in four of intermittent
exotropia studies [4, 66, 68, 74].
The outcome measurement used to assess stereoacuity
were similar to those found in amblyopia studies, “Ran-
dot stereoacuity test” [71, 73, 74], with the addition of
Titmus Housefly [42, 55, 60] and TNO [52, 66, 67].
“Sensory fusion” was measured with “Worth’s 4 dots”
test in two studies [42, 67]. In one review, a stepwise ap-
proach of assessing binocularity was undertaken. After
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Table 2 Strabismus outcome measures and measurements
Outcome measure
domain
Studies reported the
outcome measure
(n/33)
Variable subdomains of outcome
measure
Variable outcome measurements References
Motor alignment 26 (79%) Motor alignment /
angle of deviation 26
Orthotropia or microtropia 1
Manifest strabismus 1
Hyperdeviation 1
Prism and alternate cover test 12
Simultaneous prism and cover test 8
Cover-uncover test 5
Synoptophore 4
Alternate cover test 3
Hirschberg test 3
Krimsky 3
Prism Bar Cover Test 1
Prism under cover test 1
Corneal reflection tests 1
[2, 4, 5, 42, 52–60, 63,
65–68, 70, 71, 74–79]
Binocularity 21 (64%) Presence and quality of binocularity
/binocular single vision 9
Stereoacuity at near 8
Steroeacuity at near & distance 4
Sensory fusion 2
Randot stereoacuity test 3
TNO 3
Titmus Housefly 3
Bagolini glasses 2
Worth’s 4 dot test 2
Frisbye Davis Distance (FD2)
stereotest 1
Simultaneous perception 1
Suppression 1
Presence of monofixation 1
[2, 4, 5, 42, 52, 53, 55–
60, 66–68, 71, 73, 75–
77, 79]
Adverse events 20 (61%) Induced A or V pattern 2
Induced vertical deviation 2
Development of DVD 2
Induced incomitance 2
Intolerable diplopia 2
Development of amblyopia 2
Induced ptosis 2
Long-term Change: re-operation rate/
recurrence /overcorrection/post-opera-
tive drift 2
Subconjunctival haemorrhage 1
Discomfort/abnormal
sensory experiences 1
Tangent screen (in degrees) 1 [2, 4, 5, 42, 53–56, 58–
61, 63, 65, 68–71, 76,
78]
Health-related quality
of Life
16 (48%) Improvement in quality of life 14
Patient satisfaction 2
Anxiety 1
Depression 1
Social anxiety and social avoidance 1
Well-being 1
Intermittent Exotropia Q 6
Amblyopia and Strabismus Q 4
Adult Strabismus Q 4
Age-specific QoL assessments 2
SF-36/ SF-8/ SF-12 2
EQ-5D 2
NEI-VFQ 2
VF-14 2
EYE-Q 2
Quality of life questionnaires 2
Vision-specific quality-of-life instru-
ments 1
Any measure of patient or parent
satisfaction relating to improvement
to lifestyle 1
VFQ-25 1
The amblyopia treatment index 1
CVFQ 1
VQoL_CYP 1
CAT-QoL 1
PPQ 1
LVP-FVQ 1
[2, 4, 5, 50, 51, 53, 57,
58, 61, 62, 64, 65, 72,
73, 78, 79]
Visual acuity 8 (24%) VA tests/BCVA 5
Amblyopia 3
Log MAR or log MAR equivalent 4
Snellen 1
[42, 52, 59, 63, 73, 77–
79]
Control of deviation 8 (24%) Control 7
Control of the near angle 1
Ability to maintain /control phoria
with a filter 1
Control of DVD 1
Newcastle
Control Score 5
Holmes and Mohney Office Control
Scale 2
Mayo Score 2
Petrunak and Rao’s five-point Scale 1
[5, 52, 59, 68, 74, 76, 78,
79]
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“stereoacuity” (the gold standard), “simultaneous percep-
tion” and “motor fusion” were considered next [53].
Adverse events These included postoperative alignment
complications such as “induced A or V pattern” [60, 70],
“induced vertical deviation” [2, 54] “development of
DVD” [56, 60], “induced incomitance” [69, 71], or visual
complications such as intolerable diplopia [2, 65] and
“development of amblyopia” [4, 53].
Other adverse events specified in included studies
were “globe perforation” [65, 70, 78], and “induced pto-
sis” post botulinum toxin injection [2, 53, 54].
Long-term change following surgical procedures in-
cluding “recurrence of deviation” [68], “overcorrection”
[4, 78] and “re-operation rate/number of operations
needed” [53, 55, 65, 78] were reported.
HRQoL This was assessed using different questionnaires
that could be generic (for example SF-36) [61, 62], or
specific to age (for example EYE-Q) [77, 78], specific to
vision (for example VFQ-25) [58] or specific to condition
(for example the IXTQ) [5, 50, 51, 62, 72, 77].
Strabismus and amblyopia were often combined in the
same HRQoL questionnaire (for example the A&SQ)
[50, 61, 62, 64].
Visual acuity Only 24% of included strabismus studies
reported BCVA as an outcome measure. LogMAR or
LogMAR equivalent was the most reported unit used
[42, 52, 63, 79].
Control of deviation This outcome measure was re-
ported in seven intermittent exotropia studies [5, 52, 68,
74, 76–78]. Different scores were used including “New-
castle Control Score” [5, 52, 68, 77, 78], “Office Control
Score” [5, 74], “Mayo Score” [77, 78] and “Petrunak and
Rao’s five point scale” [52]. “Control to show whether
the deviation is latent or manifest” was also considered
for DVD in the review by Christoff et al. [59].
Fusional vergence A further outcome was referred to
as “fusional vergence for distance and near” in three [2,
66, 68] or as “motor fusion at distance or near or both”
in two studies [4, 42]. It was measured in one included
study using a “base out or base in prism test/synopto-
phore” [42] or “a prism bar” [66].
Table 2 Strabismus outcome measures and measurements (Continued)
Outcome measure
domain
Studies reported the
outcome measure
(n/33)
Variable subdomains of outcome
measure
Variable outcome measurements References
Fusional vergence 5 (15%) Fusional vergence or amplitude for
distance and near 3
Motor fusion test at near or distance
or both 2
Base out or base in prism test/
Synoptophore 1
A prism bar 1
[2, 4, 42, 66, 68]
Economic outcomes 4 (12%) Economics (e.g. length of stay in
hospital, hours of surgeons time) 2
Use of health-care resources 2
NHS costs 2
Costs to families accessing the
treatments 2
[2, 65, 78, 79]
Ocular movements 3 (9%) Ocular movements 3
Inferior oblique function 1
DVD 1
DHD 1
Ordinal scale from 0 to 4+, grade 0
or 1+ is satisfactory 1
DVD grading scale of 1–4 1
DHD is measured by reversed
fixation test 1
[54, 59, 60]
Re-operation rates 2 (6%) [55, 65]
AC/A ratio 1 (3%) [52]
Abnormal head
posture
1 (3%) [59]
Presence of latent
nystagmus
1 (3%) Video-oculography 1 [59]
Detection of
strabismus using
refraction devices
1 (3%) Plusoptix Vision Screener 1 [77]
TNO The Netherland Organisation, DVD Dissociated Vertical Deviation, DHD Dissociated Horizontal deviation, BCVA Best Corrected Visual Acuity, HR-QoL Health-
related quality of life, Q questionnaire, SF Short Form, EQ5D EuroQoL-5D, EYE-Q Effects of Youngsters’ Eyesight on Quality of Life, CVFQ Children’s Visual Function
Questionnaire, VQoL-CYP Vision-related Quality of Life of Children and Young People, CAT-QoL Children’s Amblyopia Treatment Quality of Life Questionnaire, PPQ
Perceived Psychosocial Questionnaire, LVP-FVQ LV Prasad–Functional Vision Questionnaire, NEI-VFQ National Eye Institute Visual Function Questionnaire, VF-14
Visual Function Index, NHS National Health Service
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Ocular movements These were included in vertical
strabismus such as DVD [59] and inferior oblique over-
action [60]. Muscle action was documented on a grading
scale from 1 to 4 [59] or 0–4 [60].
AC/a ratio AC/A ratio was reported as an outcome in a
review by Piano et al. for the conservative treatment of
intermittent distance exotropia [52].
Timing of measurements
The time of measurement varied between studies and
did not clearly correlate with the intervention. The
measurement was often done at multiple time points
[54, 61, 63, 66, 67, 70, 78] or at one time point other-
wise. It ranged from one week [66] to three years [42,
73]. The most frequently given timings were 3months
[54, 60, 61, 63, 66, 69, 70, 72, 78], 6 months [2, 53, 54,
61, 63, 65–67, 70, 71, 74–76, 78] and one year [58, 61,
63, 64, 67]. Long-term outcomes were measured at age
of six years in one study for infantile esotropia [55].
Ocular motility disorders (OMDs)
Types of included studies
A total of 68 studies were included for ocular motility
disorders (OMDs), distributed as eight Cochrane re-
views, 12 systematic reviews, 29 controlled trials, 15
non-systematic reviews and four retrospective studies.
Types of ocular motility disorders and included age groups
We classified OMDs into seven sub-conditions. Table 3
gives an outline of the common outcome measures
across these sub-conditions in included studies.
Forty five per cent of included OMDs studies [81–116]
had adults exclusively as subjects due to the nature of
conditions under evaluation such as thyroid eye disease
and neurological diseases with gaze palsies, which exist
in adults typically. In contrast, less than tenth of the
studies were done on paediatric subjects [117–124].
Some of these were for conditions found predominantly
in teenagers such as convergence insufficiency and
accommodation dysfunction and others included disor-
ders with an early onset such as infantile nystagmus and
pattern deviations. The remaining studies had mixed
adults and children populations (n = 18/67) [80, 125–
141] or the age was not clear (n = 6/67) [142–147].
Types of treatment
Interventions used in these studies included medical,
surgical and conservative measures.
Outcome measure domains
We identified ten domains of outcome measures com-
mon for the majority of OMDs (Table 4). The most fre-
quently reported outcome measures were “range of eye
movement” (34%), “HRQoL” (28%), “improvement in
diplopia” (26%), “visual acuity” (22%) and “motor align-
ment” (21%). Other less frequent outcome measures in-
cluded “adverse events” (15%), “improvement in
symptoms” (13%), “improvement in AHP” (10%), “in-
creasing field of BSV” (6%) and “stereoacuity” (6%).
Outcome measure subdomains and measurements
Range of eye movement This was the commonest out-
come measure reported in general for OMDs and was
included in all sub-conditions except for accommodation
and convergence disorders. This was either included in
composite scores or as a distinct outcome measure. In
one RCT the nine positions of gaze were videotaped and
measurements were done “directly on photographs
drawing a horizontal straight line from internal canthus”
[102]. In another study this was described as “in 8 posi-
tions of gaze binocularly and monocularly” [132].
HRQoL HRQoL outcome measures were mostly prom-
inent in thyroid eye disease studies [82, 84, 91, 95–97,
104, 107, 109–111, 115, 116], nevertheless they were also
scattered in other sub-conditions; accommodation and
convergence disorders [125], ocular myasthenia [142]
and central causes of eye movement disorders [80, 81].
Table 3 Ocular motility disorder sub-conditions and common outcome measures
OMD sub- condition Range of eye
movement
HRQoL Diplopia VA Motor
alignment
Adverse
events
AHP Patient
symptoms
BSV Stereopsis
Accommodation & convergence
disorders
√ √ √ √
Mechanical & paralytic √ √ √ √ √ √ √
Myogenic √ √ √ √ √ √ √ √ √ √
Neurogenic √ √ √ √ √ √ √
Nystagmus √ √ √ √ √
Patterns √ √ √ √
Central causes √ √ √ √ √ √ √
OMD ocular motility disorder, HRQoL Health-related quality of life, VA visual acuity, AHP abnormal head posture, BSV binocular singe vision
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Table 4 Ocular motility disorder outcome measures and measurements
Outcome measure
domain
Studies reported
the outcome
measure (n/68)
Variable subdomains of
outcome measure
Variable outcome
measurements
References
Range of eye
movement
23 (34%) Range of eye movement/
Change in extraocular
motility 14
Determination of range of
motility 4
Oculomotor range/
amount of ductions 4
Restriction of eye
movements 3
Motility assessment 3
Quantitative measurement
of eye movement 1
Assessment of ocular
muscle contracture 1
Gradation of movements 2
A scale of − 4 underaction to +
4 overaction, with 0 being
normal 2
Forced duction test 2
The CROM score 2
A and V patterns 1
Two-step test 1
Monocular (ductions) and
binocular (versions) 1
Cover/uncover test 1
Videotaped, measured the nine
positions of gaze directly on
photographs 1
Downshoot 1
[80–82, 89, 90, 92, 93, 95, 102, 108, 111,
115, 116, 119, 121, 129, 130, 132, 134,
138, 139, 141, 144]
Health-related quality
of Life
19 (28%) Improvement in HRQoL 16
Patient satisfaction and
functional measurements
2
Participant and physician-
reported global health
assessment 1
Aesthetic outcome 1
Appearance of the eye 1
Functional outcome 1
Being able to drive after
strabismus surgery 1
Validated questionnaires 6
Short Form 36 (SF-36) 2
Sickness Index Profile (SIP) 1
Visual analogue scale 1
NEI-VFQ-25 3
Visual analogue scale 1
[80, 82, 84, 87, 91, 95–97, 104, 107, 109–
111, 115, 116, 125, 126, 142, 143]
Improvement in
diplopia
18 (26%) Recovery in diplopia 18
Disappearance of diplopia
in primary gaze 2
No diplopia in primary
position and downgaze
with prisms or without
prisms 1
Subjective diplopia score
(Gorman scale) 5
Diplopia score within GO-QOL
questionnaire 1
A field diplopia test 1
[89, 93, 101, 105, 106, 108, 111, 112, 114–
116, 119, 127, 133, 134, 141, 144, 146]
Visual acuity 15 (22%) Visual Acuity/BCVA 11
Binocular BCVA 5
Near VA 1
Estimated VA 1
Log MAR or Snellen 4
Snellen 1
Pattern reversal VEP 1
Subjective score within GO-QoL
questionnaire 1
[85–87, 96–98, 101, 108, 112, 119, 120,
124, 126, 145, 147]
Motor alignment 14 (21%) Deviation 4
Objective torsion 4
Ocular alignment
testing 2
Phoria 2
Alignment in primary
position 1
Incomitance 1
A & V pattern 1
Pattern deviation and
horizontal deviation 2
Subjective torsion 1
PACT 2
Indirect ophthalmoscopy 2
Cover tests 1
PCT 1
Krimsky 1
Synoptophore 1
Maddox rod to test
overcorrection > 20 degrees 1
Double Maddox rod test 1
[106, 110, 121, 124, 128, 130–132, 134,
136, 138–140, 147]
Adverse events 10 (15%) Related to steroids 2
Related to Rituximab 1
Related to radiotherapy 1
Related to acupuncture 1
Surgical complications 1
Vision loss/retro orbital
hematoma post
reconstruction 1
Surgery-induced
strabismus or visual loss 1
Post op drift 1
[82, 84, 93, 99, 111, 126, 127, 130, 136,
146]
Improvement in 9 (13%) CI symptoms 5 (CISS) Version-15/CISS score 6 [80, 117, 123–125, 127, 128, 137, 147]
Jabri et al. BMC Ophthalmology           (2019) 19:47 Page 13 of 22
Improvement in diplopia This was another common
outcome measure; however there was incongruity in the
position of gaze free from diplopia. Position of gaze was
mostly not indicated [90, 93, 101, 105, 112, 115, 116,
127, 133, 141, 144, 146], however improvement was con-
fined to primary gaze in a number of studies [106, 108,
114, 119].
Visual acuity Only 22% of the included studies reported
visual acuity and these were mostly for nystagmus or or-
bital abnormalities. “Binocular visual acuity” was specif-
ically additionally indicated in two of nystagmus studies
[85, 126].
Motor alignment This was reported in all
sub-conditions except nystagmus studies. Whenever re-
ported, this was either assessed with cover/uncover/al-
ternate cover test without quantification [129, 132] or
quantified using “PACT” [138, 140] or “Krimsky” [138]
in less cooperative patients. Moreover, in addition to
horizontal and vertical deviation, torsion was evaluated
in a number of pattern deviation studies objectively
[121, 136, 139, 140] or less commonly subjectively [121].
Timing of measurements
Multiple time points [82, 92, 94, 96, 97, 100, 101, 103,
115, 118, 121, 128] or spans of follow up were often
given [83, 84, 99, 105, 111, 113, 126, 139]. However 6
months [82, 83, 97, 99, 103, 104, 111] and 12months
[82, 97, 98, 103, 107, 113] were frequent timings given in
thyroid eye disease studies. Twelve weeks timing was
common for accommodation and convergence disorders
[117, 118, 125, 128].
More details on included studies for amblyopia, stra-
bismus and ocular motility disorders arranged alongside
identified outcome measures, outcome measurements
and timings are given in Additional file 3: Table S31,
Additional file 4: Table S3.2, Additional file 5:: Table
S3.3 and Additional file 6: Tables S4.1–4.7).
Outcome measures per sub-condition
Accommodation and convergence disorders (n = 7)
(Additional file 6: Table S4.1)
For this group of disorders, the most prominent out-
come measures were “patient symptoms” recorded with
“Convergence Insufficiency Symptom Survey (CISS)”
(86%). “Near point of convergence NPC” and “positive
fusional vergence” were less common. Alignment meas-
urement was not expansively assessed in included stud-
ies apart from measuring “phoria” in two studies [128,
147] or ruling out manifest strabismus with “cover test
at distance and near” for inclusion in one trial [124] .
“Amplitude of accommodation” [118, 128, 147], and “ac-
commodative facility” [118, 147] were also reported.
“Dynamic retinoscopy” was reported by one study [147].
Ocular mechanical restriction (n = 6) (Additional file 6: Table
S4.2)
The outcome measures “resolution of diplopia”, “motility
assessment” and “alignment” were mutual with other
OMDs.
However, in certain circumstances such as in acute or-
bital floor fractures, the outcome measures
Table 4 Ocular motility disorder outcome measures and measurements (Continued)
Outcome measure
domain
Studies reported
the outcome
measure (n/68)
Variable subdomains of
outcome measure
Variable outcome
measurements
References
symptoms Ocular myasthenia
symptoms 1
Oscillopsia or blur in
nystagmus 1
Patient-reported
symptoms post brain
injury 1
Patient record or notes/
questionnaire 1
Improvement in
abnormal head
posture
7 (10%) (In degrees) 2
Inspection 1
[106, 120, 126, 129, 131, 132, 134]
Increasing the field
of binocular single
vision (BSV)
4 (6%) Goldman
perimeter with the
score system of
Sullivan 1
Worth four dot test 1
CROM device 1
[80, 110, 130, 134]
Stereopsis 4 (6%) Presence of stereopsis 2
Steroacuity 2
TNO stereo test 1 [80, 106, 124, 140]
HR-QoL Health-related quality of life, Q questionnaire, CROM cervical range of motion, NEI-VFQ National Eye Institute Visual Function Questionnaire, SF Short Form,
BCVA Best Corrected Visual Acuity, VEP Visual Evoked Potential, GO-QoL Graves Ophthalmopathy Quality of Life, APCT Alternate Prism Cover Test, PCT Prism Cover
Test, TED Thyroid Eye Disease, CISS Convergence Insufficiency Symptom Survey, TNO The Netherland Organisation
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“oculocardiac reflex” [119],“visual acuity” [119, 141] and
“pupillary function” [119] were important.
“Assessment of fractures and entrapment of soft tis-
sue” was evaluated with radiographic imaging such as
helical CT [119].
“Forced duction test” was reported to check muscle re-
striction and entrapment in two included studies [119,
122]. Other assessments done in orbital fractures in-
cluded “globe integrity” [119], “globe dystopia” [119,
122] and “infraorbital hyposthaesia” [105, 119, 141]. A
further outcome measure related to appearance was
“resolution of enophthalmos” [105, 141, 146].
Ocular myogenic disorders (n = 30) (Additional file 6: Table
S4.3)
Thyroid eye disease Treatment response in thyroid eye
disease is commonly evaluated using composite scores
such as “VISA” [109] and “EUGOGO score” [91, 92,
103]. Modified versions of existing scales are often de-
veloped and used (for example “modified EUGOGO”
[101], and “modified Werner grading scale” for orbital
inflammation [96]). In addition, we found a high fre-
quency of a number of widely recognised scoring sys-
tems such as “The clinical activity score (CAS)” to assess
disease activity [82, 84, 90, 92, 95, 97–99, 101, 103, 104,
108, 110–112, 114–116] and “NO SPECS” to assess dis-
ease severity. [82, 84, 90, 103, 104, 111].
“Subjective diplopia” was frequently assessed using “the
Gorman diplopia score” [90, 95, 116]. Ocular muscle mo-
tility assessment was mostly involved within composite
scores but occasionally measured with dedicated scores
(for e.g. The Total Motility score (TMS)) [116]. Additional
outcome measures reported by studies for thyroid eye dis-
ease included “the need for post treatment corrective pro-
cedures” [83, 84, 91, 98, 111], and “orbital volume/orbital
fat and muscle volume”. [95, 112].
Ocular myasthenia gravis and progressive external
ophthalmoplegia In addition to the previously stated
outcome measures shared with other eye motility disor-
ders such as “improvement in diplopia” [127, 133] and
“eye movement measurement” [102], there were out-
come measures specific to myasthenia reported by in-
cluded studies. These included “quantitative ocular
myasthenia gravis score (OMG) score” [142] and “pro-
gression to generalised myasthenia gravis” [127, 133,
142]. Other associated ocular motility abnormalities re-
ported included “inter-saccadic fatigue”, “gaze-paretic
nystagmus”, “fatigue of accommodation” and “reduced
velocity of pupillary constriction” [133]. Quality of life
was evaluated using “the 15-item Myasthenia Gravis
quality of life scale” in one study [142].
Ocular motility disorders secondary to neurogenic disorders
(n = 6) (Supp. Table 4.4)
These refer to conditions such as third, fourth and sixth
cranial nerve palsies. Clinical outcome measures in-
cluded here in addition were “palpebral fissure size” [93,
144] and “pupil size” [144] for third nerve palsy. Bi et al.
used “The cervical range motion (CROM) score” to
quantify diplopia in a pilot RCT on acupuncture for the
treatment of oculomotor paralysis [93].
In the review by Engel, in congenital fourth nerve
palsy, alignment was checked with “a more sensitive
2-step test” [131]. “Facial asymmetry” was evaluated, and
“superior oblique muscle atrophy/absent trochlear
nerve” were examined with “high definition MRI” in the
same study [131]. “Abnormal head position” was mea-
sured objectively using “a goniometer” in degrees [131].
An important adverse event sought after treatment here
included “secondary Brown syndrome” [131].
In sixth nerve palsy, motility outcomes were included
to reveal any “degree of incomitance” while measuring
deviation, and to check for “medial rectus muscle con-
tracture” using “forced duction test” [130]. “Scott’s force
generation test” or “electrooculography/electromyog-
raphy” were used to assess “lateral rectus muscle func-
tion” [130].
Nystagmus (n = 8) (Additional file 6: Table S4.5)
Outcome measures that were shared with most of the
remaining OMDs were “visual acuity” (75%) [85–87,
120, 126, 145], “improved head posture” (25%) [120,
126], “patient satisfaction” (25%) [87, 126] and “range of
eye movement” (13%) [132]. However, it is important to
note that vision in patients with nystagmus was assessed
more comprehensively with additional specifications in a
few studies; “binocular visual acuity” was reported in
two studies [85, 126], “gaze-dependant visual acuity
GDVA” in one study [86], “near visual acuity” in one
study [87] and “estimated visual acuity using pattern re-
versal VEP” in one study for infantile nystagmus [126].
“Eye movement recordings” was included in six nys-
tagmus studies (75%) [85–87, 126, 132, 145]. Examples
of the methods used to record eye movement included
“3-D video-oculography” [87] and “an infrared video
pupil tracker” [86]. Different specific characteristics of
nystagmus were gathered from eye movement record-
ings including “foveation/recognition time” [126, 137],
“broadening the null point” [137, 145], and “nystagmus
waveform” [126, 145]. The specific symptom of “oscil-
lopsia” was assessed in two included studies [120, 137].
Pattern deviation (n = 5) (Additional file 6: Table S4.6)
A special feature with this group of conditions was the
torsion deviation measurement reported in 80% (n = 4/5)
of studies [121, 136, 139, 140]. “Objective torsion” using
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“indirect ophthalmoscopy” was more commonly re-
ported [121, 136, 139, 140] than “subjective torsion
using double Maddox rod test” [121]. An example of a
grading scale used was “-4 underaction to +4 overaction
with 0 being normal” [121].
Ocular motility disorders secondary to central causes (n = 7)
(Additional file 6: Table S4.7)
These include gaze palsies and some forms of acquired
nystagmus. In addition to the common outcome mea-
sures with other sub-conditions, there were others
highlighted in a number of included studies. These com-
prised particular attention to “saccades and pursuits”.
Measurements were done using “the optokinetic drum”
or “video-oculogarphy” [132]. “Near point of conver-
gence” was reported in one study [106].
Discussion
Systematic reviews investigating various specialities in-
cluding ophthalmology [148–151] are increasingly being
performed. What is evident from many systematic re-
views is that the results from included trials and studies
cannot be meta-analysed because of the variation in out-
come measures used across the studies. The COMET
initiative calls for development of COS in order to pro-
vide a minimum set of outcome measures which will fa-
cilitate future synthesis of results. To our knowledge this
is the first review using systematic methods in accord-
ance with the COMET handbook aiming to develop an
item bank of outcome measures in the treatment of am-
blyopia, strabismus and ocular motility disorders.
We chose to combine these conditions in one report
due to the great overlap between them and their fre-
quent co-existence in subjects. Indeed some might con-
sider strabismus as a subset of ocular motility disorders
and vice versa. For example esotropia from sixth cranial
nerve palsy was classified under motility disorders while
others may classify it under strabismus. Additionally,
strabismus can cause or result from amblyopia, and
similarly with ocular motility disorders with childhood
onset. Therefore it is meaningful to consider them all in
one generalised report.
Although we did not cover every type, this review in-
cludes outcome measures extracted from studies investi-
gating a wide range of amblyopia, strabismus and ocular
motility disorders in different age groups undergoing
nearly all possible methods of interventions.
Amblyopia
Although we attempted to include all types of amblyopia
in this paper, we found that the majority of the studied
variants were anisometropic, strabismic and combined
anisometropic and strabismic amblyopia. Even though
aetiologies were different, therapeutic interventions and
outcome measures were comparable.
This review found that VA is the only outcome meas-
ure agreed by the great majority of included amblyopia
studies. Stereopsis, adverse events and HRQoL were also
relatively common however they were reported by less
than half of the studies. VA and stereopsis measurement
methods largely depended on the age of subjects who
were mostly from the paediatric age group.
BCVA is measured typically in children from around
the age of 3–4 years as well as in adults. It is the most
commonly used outcome to assess visual acuity in our
review and in perhaps in general for any eye condition.
However, it is increasingly recognised that it does not
truly reflect visual function needed in normal daily activ-
ities [151]. Additional assessments that can give more
information about visual function include contrast sensi-
tivity, near visual acuity, reading speed and visual field
sensitivity [151].
It is not uncommon to find older children and adults
with residual amblyopia, and as a result various
non-conventional therapies attempted to treat it beyond
the plasticity period. When that is done visual function
can be assessed using conventional methods in addition to
more objective and sensitive methods especially in the re-
search environment. VEP is one outcome measure used to
assess visual function post treatment in older children and
adults. It is recommended to use VEP latency rather than
amplitude due to its higher sensitivity [46].
Due to the strong association between amblyopia and
strabismus, we made the assumption that ocular align-
ment would be a standard outcome measure in ambly-
opia studies, which was not the case once results had
been gathered and analysed. Only 12% of the studies in-
cluded this outcome measure.
Regarding health-related quality of life, it is notable
that treatment side effects and compliance are occasion-
ally evaluated and reported within HRQoL question-
naires, i.e. collecting all subjective or patient-reported
outcomes in one type of a composite score. Therefore a
number of amblyopia studies that reported HRQoL did
not consider adverse events or compliance as independ-
ent outcome measures.
The timing of reported measurements was variable be-
tween studies however the most frequent time point
found here was 12 months.
Strabismus
There is nearly a total agreement on the necessity to
measure motor alignment at distance and near using
prism alternate cover test (PACT) or simultaneous prism
cover test (SPCT) in ideal situations; and Krimsky in
poor cooperation or low vision [60]. The difference be-
tween PACT and SPCT is that the first measures the
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alignment by covering each eye alternatively whereas the
second measures alignment before binocular vision is
disrupted. Generally the total misalignment measured by
PACT is the most often one reported [77].
The other outcome measures reported by more than
half of strabismus studies were “binocularity (stereopsis/
BSV)” and “adverse events”. “HRQoL” was reported by
just under half of included studies.
Binocularity was mostly measured in included studies
using near stereopsis. We found that distance stereopsis
is not typically assessed with the exception of intermit-
tent exotropia. A moderate correlation was found be-
tween near and distance stereoacuity in previous studies
[66] and most clinicians prefer to measure near stereoa-
cuity over distance stereoacuity because of better patient
cooperation [5]. On the other hand, some authors sug-
gest that distance stereoacuity is a better indicator for
intermittent exotropia progression [66]. For example, in
the RCT conducted by Saxena et al., distance stereoa-
cuity showed continued improvement for up to three
months post treatment compared to one week for near
stereoacuity [66].
HRQoL is a complex concept with wide variation in
how people perceive it individually and within one indi-
vidual over time [62]. There is no agreed definition of
QoL [51] however it can be considered a reflection of
one’s overall well-being and life experience, which is af-
fected by different factors including physical, psycho-
social and environmental elements [62]. McBain et al.
found that adults with strabismus can have one of two
types of QoL concerns; for example there may be func-
tional concerns for those with diplopia and psychosocial
concerns for those with strabismus but no diplopia [62].
It must be highlighted that the aim of measuring
HRQoL outcome is to provide appropriate support de-
pending on specific concerns or needs. It seems never-
theless that there is still no total consensus on one
method of measurement of HRQoL in strabismus and
amblyopia and that there is room for further develop-
ment to reach agreement.
In comparison to the agreement on the above mea-
sures, there was dissimilarity in measuring other out-
come measures such as “visual acuity” and “control of
deviation” for patients with strabismus.
This review found only one third of strabismus studies
considering “visual acuity” important to measure after
treatment. This could be partially explained by the fact
that it is relevant mostly in children to check the status
of amblyopia and that vision is not a primary concern
when there is prior amblyopia in adults undergoing for
example surgical correction.
Furthermore, there are a number of outcome measures
relevant only in specific variants of strabismus for ex-
ample “control of deviation” and “AC/A ratio”. Control
of deviation is pertinent mostly in cases of intermittent
exotropia and DVD. AC/A ratio is important mostly in
high AC/A esotropia.
“AC/A ratio” is often measured for intermittent exo-
tropia as well. It was shown previously by some authors
that lower AC/A ratios were attained post extensive
orthoptic exercises for intermittent distance exotropia
[52]. However, due to technical difficulties in measure-
ments and potential inaccuracies if occlusion is not used
while measuring it to differentiate between true and
pseudo divergence excess, it is challenging to use it as a
standard test to guide treatment [52].
Six months was the most commonly given timing to
report outcome measures post strabismus treatment al-
though there was great variation between studies.
Ocular motility disorders
Agreement on outcome measures for OMDs was the least
compared to amblyopia and strabismus probably due to
the wider variation in clinical features and therefore we
provided outcome measures per sub-condition. However
we found a degree of overlap in some outcome measures
between the seven categories such as “range of eye move-
ment”, “HRQoL” and “improvement in diplopia”.
Generally, it seems that having a satisfactory “range of
eye movement” was the preferred outcome measure in
eye motility disorders and that measurement in both
ductions and versions is recommended to differentiate
restrictive from paralytic eye conditions.
“HRQoL” assessment was shown to be especially rele-
vant in disfiguring conditions such as thyroid eye dis-
ease. The reason behind that is the previously noted
psychological factors which do not correlate well with
objective clinical measures for unclear reasons [107].
There have been various versions of Graves’s ophthalmo-
pathy QoL questionnaires, but once more there is no
consensus regarding their use [109]. A common feature
in such questionnaires however is addressing both visual
and appearance-related aspects of QoL [97, 107, 110].
Some authors considered in addition evaluating
long-term quality of life in this group of patients for up
to 11 years [107].
Furthermore, for OMDs complicated with “diplopia”, a
primary outcome measure frequently emphasised here
was to assess improvement or resolution of diplopia.
However, it would be useful, we suggest, to have an
agreement whether any improvement in diplopia would
be acceptable or improvement in diplopia in primary
gaze, down gaze, with or without prisms would be re-
quired to define success. Also whether subjective reports
are sufficient or they need to be combined with objective
measurement of “field of binocular single vision”. Simi-
larly for measurement of deviation or reporting “align-
ment”, an indication whether orthophoria in primary
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gaze or in more positions of gaze to be planned or
achieved would be more helpful.
“Improvement in head posture” was found often
closely related to improvement in diplopia and align-
ment, however this review has shown that it was not
consistently addressed in relevant studies. Reporting
head posture improvement in relation to the null pos-
ition was similarly incongruous in nystagmus studies.
On the other hand, when diplopia was not the only
concern in the ocular motility disorder as in accommo-
dation and convergence disorders, “improvement in
symptoms” would be reported. “The Convergence Insuf-
ficiency Symptom Survey” appeared to be widely ac-
cepted for this purpose [117, 123, 125, 128, 147].
Although assessment of “visual acuity” is typically stand-
ard in eye conditions, it was not reported in 75% of in-
cluded OMDs studies. As noted above, its measurement
was shown to be vital in nystagmus patients mostly. How-
ever, consensus is needed about what category of visual
acuity to measure. Vision assessment was also relevant in
thyroid eye disease and orbital fracture for optic nerve
function assessment in relation to orbital changes.
Timing of reported outcome measures here was vari-
able due to various factors indicated above.
Study strengths and limitations
The strength of this work is that the review followed a
prescribed process for the creation of an item bank of
outcome measures [7]. The resultant item bank is a
comprehensive list that underpins the first stage of the
process to develop Core Outcome Sets for amblyopia,
strabismus and ocular motility disorders.
On the other hand, despite some overlap between tar-
get conditions, the varied review scope and inclusion of
a wide range of conditions together could be considered
a limitation preventing us from finding all the relevant
reported outcome measures for every target condition
and sub-condition. Although generalised and overlap-
ping outcome measures for amblyopia, strabismus and
ocular motility disorders were extracted here, specific
and more refined categories of outcome measures might
have been overlooked.
Another potential limitation is the exclusion of other
studies of lower quality than systematic reviews and con-
trolled trials, which might have resulted in missing valu-
able sources of reported outcome measures in literature.
It would not be possible however to include all types of
studies for a wide group of conditions as in our review.
This might be feasible for conditions/sub-conditions
when investigated individually.
Future work and recommendations
We next plan to conduct an iterative consensus process
(Delphi surveys and group meetings) with key
stakeholders including patients, clinicians and re-
searchers as the second stage of developing these COSs.
This stage will be to standardise what to measure, i.e.
outcome measures. Subsequent work will be required to
standardise how to measure them, i.e. outcome measure-
ments and later, when to measure them, i.e. timing of
measurements.
In terms of developing “Core Outcome Sets”, we sug-
gest the inclusion of both subjective and objective out-
come measures; and both positive (i.e. improvement
from baseline) and serious negative outcomes (i.e. ad-
verse events). Furthermore, choosing feasible and easily
available assessments is important. We also recommend
that “long-term outcomes”, especially for known chronic
conditions, are considered.
Conclusions
We generated lists of the most reported outcome mea-
sures for amblyopia, strabismus and ocular motility dis-
orders within included studies with indications to
specific outcome measures in certain sub-conditions.
We also identified the most reported outcome measure-
ments and their timings from intervention to some
extent.
This review also demonstrates significant variation in
outcome measure reporting within published studies in
the three conditions confirming the challenge in efficient
comparison, combination and synthesis of data.
Various factors might be responsible for inconsistency
between studies in reported outcome measures in condi-
tions targeted in this review including age group, type of
condition and often researcher or clinician preferences.
While some of these factors are understandably fixed,
researchers and clinicians preferences can probably be
unified and standardised.
Although common outcome measures and measure-
ments from the literature are highlighted in this review,
this does not imply that they are necessarily the most
appropriate outcome measures to be used as “core out-
come measures” in trials or clinical practice. Consensus
among all stakeholders including patients, clinicians, and
researchers is required to establish COS. International
agreement would be ideal to maximise usefulness of re-
search overall.
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